@article{Hummel:2006,
	title = {{A biological definition of Burkitt's Lymphoma from transcriptional
	and genomic profiling}},
	author = {Michael Hummel and Stefan Bentink and Hilmar Berger and Wolfram Klapper and Swen Wessendorf and Thomas F.E. Barth and Heinz-Wolfram Bernd and Sergio B. Cogliatti and Judith Dierlamm and Alfred C. Feller and Martin-Leo Hansmann and Eugenia Haralambieva and Lana Harder and Dirk Hasenclever and Michael K"uhn and Dido Lenze and Peter Lichter and Jose Ignacio Martin-Subero and Peter M"oller and Hans-Konrad M"uller-Hermelink and German Ott and Reza M. Parwaresch and Christiane Pott and Andreas Rosenwald and Maciej Rosolowski and Carsten Schwaenen and Benjamin St"urzenhofecker and Monika Szczepanowski and Heiko Trautmann and Hans-Heinrich Wacker and Rainer Spang and Markus L"offler and Lorenz Tr"umper and Harald Stein and Reiner Siebert},
	journal = {The New England Journal of Medicine},
	number = {23},
	pages = {2419--2430},
	url = {http://content.nejm.org/cgi/content/abstract/354/23/2419},
	volume = {354},
	year = {2006},
	biburl = {http://www.bibsonomy.org/bibtex/2bcd07c7b363a2386eb5b3a4b413496ac/tkirsten},
	abstract = {Background The distinction between Burkitt's lymphoma and diffuse
	large-B-cell lymphoma is unclear. We used transcriptional and genomic
	profiling to define Burkitt's lymphoma more precisely and to distinguish
	subgroups in other types of mature aggressive B-cell lymphomas.
	
	Methods We performed gene-expression profiling using Affymetrix U133A
	GeneChips with RNA from 220 mature aggressive B-cell lymphomas, including
	a core group of 8 Burkitt's lymphomas that met all World Health Organization
	(WHO) criteria. A molecular signature for Burkitt's lymphoma was
	generated, and chromosomal abnormalities were detected with interphase
	fluorescence in situ hybridization and array-based comparative genomic
	hybridization.
	
	Results We used the molecular signature for Burkitt's lymphoma to
	identify 44 cases: 11 had the morphologic features of diffuse large-B-cell
	lymphomas, 4 were unclassifiable mature aggressive B-cell lymphomas,
	and 29 had a classic or atypical Burkitt's morphologic appearance.
	Also, five did not have a detectable IG-myc Burkitt's translocation,
	whereas the others contained an IG-myc fusion, mostly in simple karyotypes.
	Of the 176 lymphomas without the molecular signature for Burkitt's
	lymphoma, 155 were diffuse large-B-cell lymphomas. Of these 155 cases,
	21 percent had a chromosomal breakpoint at the myc locus associated
	with complex chromosomal changes and an unfavorable clinical course.
	
	Conclusions Our molecular definition of Burkitt's lymphoma clarifies
	and extends the spectrum of the WHO criteria for Burkitt's lymphoma.
	In mature aggressive B-cell lymphomas without a gene signature for
	Burkitt's lymphoma, chromosomal breakpoints at the myc locus were
	associated with an adverse clinical outcome.},
	owner = {tkirsten},
	keywords = {imported }
}